Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 4 of 4 results for fostamatinib

  1. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Published
    19 October 2022
    View recommendations

    Sections for TA835

  2. Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.

    Technology appraisal guidance
    Published
    15 December 2022
    View recommendations

    Sections for TA853

  3. Past appeals and decisions

    Past technology appraisal appeals and decisions

  4. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA759)

    This guidance has been updated and replaced by NICE technology appraisal guidance 835.

    Technology appraisal guidance
    Published
    7 January 2022